The HPSE inhibitor OGT2115 did not affect osteogenic differentiation of mouse BM-MSCs. (A) The expression levels of Hpse1 increased during osteogenic differentiation. (B) Osteogenic potential was characterized by ARS staining after 21 days induction at the fourth passage of BM-MSCs with or without OGT2115. Quantifications of ARS staining of OGT2115 and control groups showed no difference (n = 3). (C) Quantitative real-time PCR analysis on the mRNA expression levels of Mmp2, Mmp9 and Mmp14 with or without the treatment of OGT2115 detected a significantly increased Mmp9 expression when HPSE1 is enzymatically inhibited. Error bars represent standard deviation.